US Veterans Affairs will pay for some to get new Biogen-Eisai Alzheimer’s drug
Leqembi, the first Alzheimer’s treatment to slow cognitive decline, will be available for US patients that meet strict criteria after requesting the treatment.
By John Tozzi and Robert Langreth, bloomberg
The US Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly Alzheimer’s drug fails to prevent disease in trial
For subscribers
.jpg&w=384&q=75)
